Gladius Capital Management’s Gilead Sciences GILD Stock Holding History

Gladius Capital Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-418	Closed	-$33.9K	–	352
2023 Q4	$33.9K	Buy	+418	New	+$32.5K	0.01%	254
2023 Q3	–	Sell	-422	Closed	-$32.5K	–	405
2023 Q2	$32.5K	Buy	+422	New	+$33.7K	﹤0.01%	244
2022 Q3	–	Sell	-2,266	Closed	-$143K	–	422
2022 Q2	$141K	Sell	2,266 -304,851	-99%	-$18.9M	0.01%	173
2022 Q1	$18.3M	Buy	307,117 +305,590	+20,012%	+$19.5M	1.35%	17
2021 Q4	$111K	Buy	+1,527	New	+$105K	0.01%	239
2020 Q1	–	Sell	-4,022	Closed	-$262K	–	148
2019 Q4	$262K	Sell	4,022 -3,436	-46%	-$224K	0.02%	149
2019 Q3	$473K	Buy	7,458 +1,963	+36%	+$128K	0.02%	179
2019 Q2	$373K	Sell	5,495 -12,384	-69%	-$815K	0.02%	146
2019 Q1	$1.16M	Buy	17,879 +5,833	+48%	+$388K	0.06%	101
2018 Q4	$753K	Buy	+12,046	New	+$842K	0.04%	103

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Gladius Capital Management's GILD Position: Q1 2024 in Review

Gladius Capital Management sold out of Gilead Sciences (GILD) in Q1 2024, closing a stake of 418 shares — an estimated $33.9K sold.

Gladius Capital Management first reported a position in GILD in Q4 2018 and held it in 10 quarters. The position peaked at $18.3M in Q1 2022. 1,721 funds tracked by Wall St. Rank hold GILD as of Q1 2024.

Gladius Capital Management reported no remaining Gilead Sciences position as of Q1 2024 after selling out during the quarter.
Gladius Capital Management sold 418 Gilead Sciences shares in Q1 2024, an estimated $33.9K.
Gladius Capital Management first reported a position in Gilead Sciences in Q4 2018 and held it in 10 quarters.
Gladius Capital Management's Gilead Sciences position peaked at $18.3M in Q1 2022.
1,721 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2024.

Based on Gladius Capital Management's 13F filing for Q1 2024, filed 14 May 2024.